strength core us busi row mask well
improv gm take near-term back seat row devic
soft dilut data-gener invest
long-term thesi intact remain ow
invest thesis/summari see long-term support larg instal
iv on-going oper leverag near term see two headwind row
devic segment growth low cycl period benefit favor
reimburs chang ii ep dilut verili propel heath
point report global mask sale constant fx
outpac global devic sale contribut higher gm vs mse
ii row devic weaker one quarter earlier expect constant fx
favor regulatori chang franc japan lap iii ep
dilut verili per quarter propel health
per quarter mildli larger expect
differ see less gm pressur past year
us reimburs favor ii upsid traction mobi
portabl oxygen concentr long term iii recoveri row
devic high growth period lap
dilut softwar invest expertis patient connect
within osa ecosystem born fruit patient complianc improv
resuppli move higher propel health near-term dilut may open
copd market lead downstream refer inhal patient
poc/vent diseas progress verili health jv also near-term dilut
may lead higher diagnosi rate osa suffer support long-term cpap
valuat sit vs coverag reduc estim due
softer row growth dilut propel health verili remain
ow still prefer stock trade ep vs australian
off-shore growth earner ew-rat ep
up/downsid price target
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
exhibit statist resm cdi
price target convert cdi
cdi disclaim end report morgan stanley research
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
analyst employ non-u affili regist
finra may associ person member may
subject nasd/nys restrict commun
subject compani public appear trade secur held
wide dispers outcom exist
wide dispers outcom exist
equival base case dcf
us devic growth higher current forecast addit small move
mask turn see upsid poc reach share
appli dcf valuat forecast includ step us
growth rate associ new product launch decay pa long
bear case assum reduct us mask price reduct us unit
growth remain intern level pa poc remain
rate ow market share gain
increas instal base support
futur posit momentum sale
consum enhanc confid
long-term sustain ep growth
product launch without rmd
top line would revert market growth rate
less price declin pa
weather cost increas line cpi
growth rate possibl owe
under-penetr osa suffer co-
high growth high-margin
therapi repeat mask/dispos sale
occur
upsid at-hom diagnosi de-
bottleneck clinic pathway
data uptak competitor next-
traction upcom launch three new
exhibit bear bull device/mask asp gm biggest valu driver
mask turn
mask turn
pressur gm
next
risk achiev price
advers impact us competit bid
continu loss cpap market share
eur usd continu deterior
result review
saa revenu grew vs mse first-tim inclus matrixcar
well healthcar first acquir juli
due complet connect devic upgrad program japan franc
expect growth slow forecast mask vs mse
gross margin beat plu oper leverag gm expand
vs mse sg revenu vs mse
continu fall revenu line expect
sg revenu line mse
non-gaap ep flat vs ep ahead mse
vs con beat attribut lower-than-expect tax rate vs
mse due onetim tax benefit expect tax rate
row devic growth surpris downsid subsequ
lower row devic sale remaind lead drop
row devic revenu line lower comp carri forward lead lower revenu
segment still expect devic growth return
market growth compani indic around mid singl digit
back recent acquisit activ compani expect net interest expens
step state second half net interest expens
million per quarter would recognis
lose relat verili jv per quarter remaind
compani expect sale previous
guidanc low end attribut
increas recent acquisit
 guidanc increas sale previou guidanc
sale state currenc movement recent acquisit
driver behind step
chang neg impact top line earn forecast
ep fall row devic growth main driver
lower revenu higher interest loss associ verili jv
exhibit chang estim follow
view longer-term-depend dcf valuat methodolog
appropri employ determin forward price target
fallen due neg earn revis
bull bear case valuat fall due lower base case
main dcf assumpt unchang shown exhibit exhibit
debt
equiti
npv cashflow
valu equiti
share issu
price target convert cdi
investor awar calcul take account
issu risk associ invest adr includ limit
liquid vote right dividend volatil currenc exchang rate
profit loss
growth pcp
growth pcp
abn extra tax
return asset
return equiti
growth pcp
growth pcp
growth pcp
growth pcp
growth pcp
growth pcp
growth pcp
fy sale
 fy ebit
dep amort
gross cash op ns
inc dec wk cap
chg loan
net chg cash
note provid research coverag list cdi associ underli ordinari share compani courtesi may includ cdi price target cdi share price aud
dollar research report unless otherwis state cdi price target convers calcul use appropri currenc exchang rate ordinari share versu cdi ratio investor awar
calcul take account issu risk associ invest cdi includ limit liquid vote right dividend volatil currenc exchang rate fluctuat
price target deriv base-cas scenario dcf
assum wacc termin growth rate
risk includ reimburs restrict us develop eu strengthen
disappoint uptak new product
price target deriv base-cas scenario dcf
assum wacc termin growth rate
potenti announc acquisit biotech/vaccines/immunolog
ii industri de-stock possibl price increas
iii uptak kcentra us
lower-than-expect adopt next-gener rcoag product
ii appreci aud usd
iii chang us reimburs environ
